Cytori to Webcast Fourth Quarter Financial Results on March 8th
Get Alerts CYTX Hot Sheet
Join SI Premium – FREE
SAN DIEGO, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) will provide a live webcast of its fourth quarter financial results and business update on Thursday, March 8, 2018 at 5:30 PM Eastern Time.
The dial-in information is as follows: | |
Dial-In Number: +1.877.402.3914 | |
Conference ID: 9689618 |
Prior to the webcast at approximately 4:30 PM Eastern Time on March 8th, Cytori will issue its fourth quarter earnings release which will review Cytori’s fourth quarter and annual performance. The webcast will be available both live and by replay two hours after the call in the “Webcasts” section of the company’s investor relations website.
About Cytori Therapeutics, Inc.
Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. Cytori Nanomedicine™ is developing liposome encapsulated therapies for regenerative medicine and oncologic indications. For more information, visit www.cytori.com.
Cytori Therapeutics, Inc.Tiago Girao, 1.858.458.0900[email protected]
Source: Cytori Therapeutics Inc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Northeast Community Bancorp, Inc. (NECB) Tops Q1 EPS by 12c
- MidWestOne Financial Group, Inc. (MOFG) Misses Q1 EPS by 15c
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!